Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McNEIL PHARMACEUTICAL NEW PRESIDENT IS FORMER MARKETING VP THOMAS ODIORNE, 44

Executive Summary

McNEIL PHARMACEUTICAL NEW PRESIDENT IS FORMER MARKETING VP THOMAS ODIORNE, 44, a 26-year veteran with the company, McNeil announced in a recent press release. Effective since April 15, Odiorne succeeded former McNeil President Jack O'Brien who was promoted to J&J VP-corporate staff for domestic trade relations and development. Included in Odiorne's new responsibilities is McNeil Pharmaceutical Ltd. of Canada. Odiorne has been marketing vice president of McNeil Pharmaceutical. After joining McNeil in 1969, Odiorne held marketing and management positions in the Southwest before moving to the company's Pennsylvania headquarters in 1977 to become product director for Tylenol with codeine, McNeil's Rx acetaminophen combo. In 1979, Odiorne assumed the position of executive director-sales, McNeil said. He followed that promotion with VP-sales in 1982 and became VP-marketing in 1982. Odiorne's early responsibilities as president will include the launch of three new products for which NDAs are currently pending: the peripheral vasodilator, cetiedil; a long-acting form of the anti-psychotic agent Haldol (haloperidol decanoate); and the calcium channel blocker bepridil, which is licensed from Carter Wallace and will be co-marketed with that firm. Another promising McNeil product is 4-hydroxyphenyl retinamide, which was recently recommended for use as a chemopreventive agent against bladder and breast cancer by the Natl. Cancer Institute Div. of Cancer Prevention and Control's Board of Scientific Counselors. The firm's dermatological anti-proliferative agent, fenretinide and two anti-diabetic agents, linogliride fumarate and methyl palmoxirate, are also currently in clinicals.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008311

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel